全文获取类型
收费全文 | 204199篇 |
免费 | 4354篇 |
国内免费 | 503篇 |
专业分类
耳鼻咽喉 | 2881篇 |
儿科学 | 7595篇 |
妇产科学 | 5899篇 |
基础医学 | 26320篇 |
口腔科学 | 6029篇 |
临床医学 | 15541篇 |
内科学 | 37337篇 |
皮肤病学 | 4570篇 |
神经病学 | 12442篇 |
特种医学 | 10997篇 |
外国民族医学 | 97篇 |
外科学 | 30932篇 |
综合类 | 1152篇 |
一般理论 | 1篇 |
预防医学 | 16487篇 |
眼科学 | 4806篇 |
药学 | 14259篇 |
2篇 | |
中国医学 | 203篇 |
肿瘤学 | 11506篇 |
出版年
2018年 | 3594篇 |
2017年 | 3944篇 |
2016年 | 3287篇 |
2015年 | 4977篇 |
2014年 | 4445篇 |
2013年 | 3644篇 |
2012年 | 10276篇 |
2011年 | 5231篇 |
2010年 | 2456篇 |
2009年 | 4085篇 |
2008年 | 2592篇 |
2007年 | 3435篇 |
2006年 | 3724篇 |
2005年 | 11900篇 |
2004年 | 13414篇 |
2003年 | 8961篇 |
2002年 | 4243篇 |
2001年 | 4477篇 |
2000年 | 1792篇 |
1999年 | 5988篇 |
1998年 | 711篇 |
1995年 | 531篇 |
1992年 | 6968篇 |
1991年 | 7216篇 |
1990年 | 7447篇 |
1989年 | 7026篇 |
1988年 | 6544篇 |
1987年 | 6299篇 |
1986年 | 6005篇 |
1985年 | 5298篇 |
1984年 | 3655篇 |
1983年 | 2959篇 |
1982年 | 1060篇 |
1981年 | 822篇 |
1980年 | 901篇 |
1979年 | 3869篇 |
1978年 | 2406篇 |
1977年 | 1819篇 |
1976年 | 1571篇 |
1975年 | 2496篇 |
1974年 | 3124篇 |
1973年 | 2753篇 |
1972年 | 2768篇 |
1971年 | 2747篇 |
1970年 | 2564篇 |
1969年 | 2469篇 |
1968年 | 2242篇 |
1967年 | 2178篇 |
1966年 | 1902篇 |
1965年 | 1136篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Buket Bakan Fatih Oltulu Yeliz Y?ld?r?m Altu? Yava?o?lu Sinan Akg?l Nefise ülkü Karabay Yava?o?lu 《Arhiv za higijenu rada i toksikologiju》2023,74(3):207
The aim of this safety study in mice was to determine in vivo toxicity and biodistribution potential of a single and multiple doses of L-glutamic acid-g-p(HEMA) polymeric nanoparticles as a drug delivery system. The single dose did not cause any lethal effect, and its acute oral LD50 was >2.000 mg/kg body weight (bw). Multiple doses (25, 50, or 100 mg/kg bw) given over 28 days resulted in no significant differences in body and relative organ weights compared to control. These results are supported by biochemical and histological findings. Moreover, nanoparticle exposure did not result in statistically significant differences in micronucleus counts in bone marrow cells compared to control. Nanoparticle distribution was time-dependent, and they reached the organs and even bone marrow by hour 6, as established by ex vivo imaging with the IVIS® spectrum imaging system. In conclusion, L-glutamic acid-g-p(HEMA) polymeric nanoparticles appear biocompatible and have a potential use as a drug delivery system.KEY WORDS: biocompatibility, blood biochemistry, genotoxicity, histology, in vivo toxicity, micronucleus test, polymers 相似文献
2.
3.
Norio Itokawa Masanori Atsukawa Akihito Tsubota Noritomo Shimada Hidenori Toyoda Koichi Takaguchi Atsushi Hiraoka Tomonori Senoh Mai Koeda Yuji Yoshida Tomomi Okubo Taeang Arai Korenobu Hayama Ai Nakagawa-Iwashita Chisa Kondo Katsuhiko Iwakiri 《Internal medicine (Tokyo, Japan)》2021,60(4):507
Objective Pegylated-interferon monotherapy is the standard treatment for patients with chronic hepatitis B; however, the factors associated with its therapeutic effects remain unclear. Methods Patients with chronic hepatitis B were treated with pegylated interferon α-2a for 48 weeks. We evaluated the kinetics of hepatitis B surface antigen (HBsAg) during treatment and follow-up periods and the factors associated with an HBsAg response (defined as a change in HBsAg of ≥-1 log IU/mL from baseline). Results The study population comprised 50 patients. The median baseline levels of hepatitis B virus DNA and HBsAg were 5.00 and 3.40 log IU/mL. The median values of HBsAg reduction from baseline were -0.44 (n=48), -0.41 (n=40), and -0.68 (n=11) log IU/mL at the end of treatment and at 48 and 144 weeks post-treatment, respectively. The rates of HBsAg response were 24.0% and 22.5% at the end of treatment and at 48 weeks post-treatment, respectively. A multivariate analysis identified HBsAg <3.00 log IU/mL as an independent baseline factor contributing to the HBsAg response at the end of treatment and 48 weeks post-treatment (p=1.07×10-2 and 4.42×10-2, respectively). There were significant differences in the reduction of the HBsAg levels at 12 weeks of treatment and in the incidence of serum ALT increase during treatment between patients with and without an HBsAg response. Conclusion These findings suggest that the baseline HBsAg level, HBsAg kinetics at 12 weeks of treatment, and ALT increase during treatment are important factors contributing to the HBsAg response in pegylated interferon α-2a monotherapy for patients with chronic hepatitis B. 相似文献
4.
5.
<正>what is the rationale for immunotherapies in Parkinsonian syndromes(PS)? PS are neurodegenerative diseases which are clinically characterized by a hypokinetic phenotype in combination with additional motor and non-motor symptoms. One major patholog- 相似文献
6.
7.
8.
9.
10.
Rodrigo Scaliante Moura Gerson Oliveira Penna Ludimila Paula Vaz Cardoso Maria Araci de Andrade Pontes Rossilene Cruz Heitor de Sá Gon?alves Maria Lúcia Fernandes Penna Mariane Martins de Araújo Stefani Samira Bührer-Sékula 《The American journal of tropical medicine and hygiene》2015,92(6):1280-1284
The uniform multidrug therapy clinical trial, Brazil (U-MDT/CT-BR), database was used to describe and report the performance of available tools to classify 830 leprosy patients as paucibacillary (PB) and multibacillary (MB) at baseline. In a modified Ridley and Jopling (R&J) classification, considering clinical features, histopathological results of skin biopsies and the slit-skin smear bacterial load results were used as the gold standard method for classification. Anti-phenolic glycolipid-I (PGL-I) serology by ML Flow test, the slit skin smear bacterial load, and the number of skin lesions were evaluated. Considering the R&J classification system as gold standard, ML Flow tests correctly allocated 70% patients in the PB group and 87% in the MB group. The classification based on counting the number of skin lesions correctly allocated 46% PB patients and 99% MB leprosy cases. Slit skin smears properly classified 91% and 97% of PB and MB patients, respectively. Based on U-MDT/CT-BR results, classification of leprosy patients for treatment purposes is unnecessary because it does not impact clinical and laboratories outcomes. In this context, the identification of new biomarkers to detect patients at a higher risk to develop leprosy reactions or relapse remains an important research challenge. 相似文献